Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fabrizio Accardi
Observed names:
F Accardi,
F. Accardi
Institution:
Ospedale Vincenzo Cervello
Observed institutions:
University of Parma,
Harvard University,
University of Pavia,
Ospedale Vincenzo Cervello,
Dana-Farber Cancer Institute,
Ospedale di Parma
show all 6
ORCID:
0000-0002-7736-2822
Observed ORCID:
0000-0002-7736-2822
OpenAlex ID:
A5041567649
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target
2016
·
Marina Bolzoni
, Martina Chiu
, et al.
·
Blood
·
182
PDF
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
2015
·
Fabrizio Accardi
, Denise Toscani
, et al.
·
BioMed Research International
·
118
PDF
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
2021
·
Jooeun Bae
, Fabrizio Accardi
, et al.
·
Leukemia
·
88
PDF
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
2017
·
Federica Costa
, Denise Toscani
, et al.
·
Oncotarget
·
74
PDF
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors
2015
·
Denise Toscani
, Carla Palumbo
, et al.
·
Journal of Bone and Mineral Research
·
63
PDF
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20
2015
·
B Dalla Palma
, D Guasco
, et al.
·
Leukemia
·
57
The osteoblastic niche in the context of multiple myeloma
2014
·
Denise Toscani
, Marina Bolzoni
, et al.
·
Annals of the New York Academy of Sciences
·
52
IL21R expressing CD14 + CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts
2017
·
Marina Bolzoni
, Domenica Ronchetti
, et al.
·
Haematologica
·
43
PDF
Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
2019
·
Valentina Marchica
, Denise Toscani
, et al.
·
Cancers
·
38
PDF
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
2017
·
Federica Costa
, Rosanna Vescovini
, et al.
·
Oncotarget
·
32
PDF
Novel targets for the treatment of relapsing multiple myeloma
2019
·
Nicola Giuliani
, Fabrizio Accardi
, et al.
·
Expert Review of Hematology
·
28
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
2023
·
Massimo Gentile
, Ernesto Vigna
, et al.
·
Haematologica
·
26
PDF
The Proteasome and Myeloma-Associated Bone Disease
2017
·
Fabrizio Accardi
, Denise Toscani
, et al.
·
Calcified Tissue International
·
26
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma
2017
·
Nicola Giuliani
, Martina Chiu
, et al.
·
Expert Opinion on Therapeutic Targets
·
26
PDF
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
2016
·
Valentina Marchica
, Fabrizio Accardi
, et al.
·
International Journal of Hematology
·
18
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
2020
·
Benedetta Dalla Palma
, Valentina Marchica
, et al.
·
Journal of Clinical Medicine
·
17
PDF
The transcriptomic profile of CD138 + cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged
2019
·
Paola Storti
, Luca Agnelli
, et al.
·
Haematologica
·
17
PDF
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
2025
·
E.A. Martino
, S. Palmieri
, et al.
·
ESMO Open
·
14
PDF
Multiple Myeloma in 2023 Ways: From Trials to Real Life
2023
·
Manlio Fazio
, Vittorio Del Fabro
, et al.
·
Current Oncology
·
14
PDF
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
2024
·
Danilo De Novellis
, Daniele Derudas
, et al.
·
European Journal Of Haematology
·
9
PDF
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis
2018
·
Fabrizio Accardi
, Valentina Papa
, et al.
·
Case Reports in Hematology
·
9
PDF
CD38 expression by plasma cells in extramedullary multiple myeloma
2023
·
Laura Notarfranchi
, Fabrizio Accardi
, et al.
·
Haematologica
·
8
PDF
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials
2024
·
Enrica Antonia Martino
, Salvatore Palmieri
, et al.
·
Hematological Oncology
·
7
PDF
Bone marrow Dikkopf‐1 levels are a new independent risk factor for progression in patients with smouldering myeloma
2017
·
Benedetta Dalla Palma
, Valentina Marchica
, et al.
·
British Journal of Haematology
·
5
PDF
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
2025
·
Sara Bringhen
, Lorenzo Cani
, et al.
·
The Lancet Haematology
·
4
Show more works
View as search
Works count:
66
Citation count:
1,002
H-index:
17
I10-index:
19
Year
Topic
Type
